Skip to content

Application of Intravenous Infusion of Remimazolam and Remifentanil in Ultrasound-Guided Gastroscopy-Assisted Endoscopic Retrograde Cholangiopancreatography

Application of Intravenous Infusion of Remimazolam and Remifentanil in Ultrasound-Guided Gastroscopy-Assisted Endoscopic Retrograde Cholangiopancreatography

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099622
Enrollment
Unknown
Registered
2025-03-26
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Diazepam and Pethidine Group:Intramuscular injection of diazepam and pethidine
Propofol and Sufentanil Group:Intermittent intravenous bolus injection of propofol and sufentanil
Remimazolam and Remifentanil Group:Intravenous infusion of remimazolam and remifentanil
Tracheal Intubation General Anesthesia Group:Tracheal Intubation General Anesthesia

Sponsors

The Affiliated Hospital of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75 years, regardless of gender; 2. American Society of Anesthesiologists (ASA) Class I-III; 3. Patients scheduled for endoscopic ultrasound (EUS)-assisted endoscopic retrograde cholangiopancreatography (ERCP) at the Endoscopy Center of the Laoshan Branch of Qingdao University Affiliated Hospital.

Exclusion criteria

Exclusion criteria: 1. Patients with ASA grade III or above; 2. Patients with severe cardiovascular and cerebrovascular diseases; 3. Patients with anticipated difficult airway, morbid obesity, asthma, alcoholism, or drug abuse; 4. Patients with contraindications or allergies to remimazolam or remifentanil; 5. Patients who have participated in other clinical studies within the past 3 months; 6. Patients who are unable to cooperate or sign the informed consent form.

Design outcomes

Primary

MeasureTime frame
Anesthesia Success Rate;

Secondary

MeasureTime frame
Modified Alertness/Sedation Scale;Anesthesia Recovery Time;Incidence of Adverse Reactions;Endoscopist and Patient Satisfaction;

Countries

China

Contacts

Public ContactNing Yu

The Affiliated Hospital of Qingdao University

yuning@qduhospital.cn+86 186 6180 7938

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026